Myra Happe

Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria

Richard L Wu, Azza H. Idris, Nina M. Berkowitz et al. · New England Journal of Medicine · 2022 · 124 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial

Melinda Hamer, Katherine V. Houser, Amelia R. Hofstetter et al. · The Lancet · 2023 · 65 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +16

Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial

Katherine V. Houser, Martin R. Gaudinski, Myra Happe et al. · EClinicalMedicine · 2022 · 44 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trial

Kirsten E. Lyke, Andrea A. Berry, Kaitlin Mason et al. · The Lancet Infectious Diseases · 2023 · 40 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +15

Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial

Emily E. Coates, Srilatha Edupuganti, Grace Chen et al. · The Lancet Infectious Diseases · 2022 · 38 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17